{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:24:36Z","timestamp":1787743476391,"version":"build-2784847793"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Science Foundation Project of Fujian Province","award":["2023J01825"],"award-info":[{"award-number":["2023J01825"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Objective: This study aimed to systematically evaluate the efficacy and safety of cadonilimab in the treatment of digestive system neoplasms. Methods: PubMed, Embase, Cochrane Library, Web of Science, Wiley Online Library, CNKI, Wanfang Data, CBM, and VIP databases were systematically searched to collect randomized controlled trials, non-randomized studies, and real-world studies investigating cadonilimab for the treatment of digestive system neoplasms. The initial search spanned from the inception of the databases to 4 February 2026, with an update search conducted in June 2026. Meta-analysis was performed using Stata 16.0 to systematically assess efficacy and safety outcomes. Results: A total of 10 studies, predominantly single-arm or retrospective, were included in this meta-analysis. Regarding the primary outcomes, because of the clinical heterogeneity across tumor types, pooled estimates should be interpreted as a summary across diverse diseases rather than as a single-tumor estimate. The overall pooled disease control rate (DCR) was 84% (95% CI = 76\u201391%), with tumor-specific DCRs of 87% in ESCC, 79% in HCC, 88% in G\/GEJ adenocarcinoma, and 86% in PDAC. The pooled incidence of any-grade treatment-related adverse events (TRAEs) was 98% (95% CI = 95\u2013100%), and the pooled incidence of any-grade immune-related adverse events (irAEs) was 32% (95% CI = 18\u201347%). For secondary outcomes: The partial response (PR) rate was 33% (95% CI = 21\u201346%), and the progressive disease (PD) rate was 11% (95% CI = 5\u201318%). The pooled incidence of grade \u2265 3 TRAEs was 52% (95% CI = 38\u201366%), and the pooled incidence of grade \u2265 3 irAEs was 11% (95% CI = 8\u201316%). However, incomplete reporting of low-frequency AEs across studies likely underestimates the pooled irAE rate. Conclusions: This study suggests that cadonilimab has the potential for antitumor activity in digestive system neoplasms. The observed safety profile was consistent with the known toxicities of immunotherapy, with notably high rates of TRAEs warranting vigilant monitoring. These findings should be considered hypothesis-generating and are insufficient to establish clinical benefit.<\/jats:p>","DOI":"10.3390\/ph19091348","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:59:23Z","timestamp":1787741963000},"page":"1348","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Cadonilimab in Digestive System Neoplasms: A Systematic Review and Single-Arm Meta-Analysis"],"prefix":"10.3390","volume":"19","author":[{"given":"Qiuqi","family":"Zhuang","sequence":"first","affiliation":[{"name":"Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Yang","sequence":"additional","affiliation":[{"name":"Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350108, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41575-022-00726-3","article-title":"Updated epidemiology of gastrointestinal cancers in East Asia","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.gtc.2022.06.005","article-title":"Squamous Cell Carcinoma of the Esophagus","volume":"51","author":"Codipilly","year":"2022","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11912-020-00975-y","article-title":"Role of Immunotherapy in Advanced Gastroesophageal Cancer","volume":"22","author":"Terrero","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00292-020-00801-z","article-title":"Hepatocellular carcinoma","volume":"41","author":"Longerich","year":"2020","journal-title":"Pathologe"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: Integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","unstructured":"Ajani, J.A., D\u2019Amico, T.A., Bentrem, D.J., Chakrabarti, S., Corvera, C.U., Das, P., Enzinger, P.C., Enzler, T., Gerdes, H., and Gibson, M.K. (2026, February 15). Esophageal and Esophagogastric Junction Cancers, Version 2.2026, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1433."},{"key":"ref_9","unstructured":"Benson, A.B., D\u2019Angelica, M.I., Abrams, T., Ahmed, A., Akce, M., Anaya, D.A., Anders, R., Are, C., Aye, L., and Bachini, M. (2026, February 15). Hepatocellular Carcinoma, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1514."},{"key":"ref_10","unstructured":"Tempero, M.A., Malafa, M.P., Basturk, O., Benson, A.B., Cardin, D.B., Chiorean, E.G., Christensen, J.A., Chung, V., Czito, B., and Del Chiaro, M. (2026, February 15). Pancreatic Adenocarcinoma, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: Opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"mAbs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): A multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e012869","DOI":"10.1136\/jitc-2025-012869","article-title":"Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma: An open-label, multicenter phase II trial","volume":"13","author":"Qu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e37616","DOI":"10.1016\/j.heliyon.2024.e37616","article-title":"Cadonilimab (PD-1\/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study","volume":"10","author":"Yuan","year":"2024","journal-title":"Heliyon"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Qiao, Q., Han, C., Ye, S., Li, J., Shao, G., Bai, Y., Xu, A., Sun, M., Wang, W., and Wu, J. (2023). The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): A phase Ib\/II single-arm clinical trial. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1238667"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00262-025-04038-8","article-title":"Cadonilimab, a PD-1\/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: A real-world study","volume":"74","author":"Wang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","article-title":"Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: The phase 1b\/2 COMPASSION-04 trial","volume":"30","author":"Gao","year":"2024","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.medj.2024.10.008","article-title":"Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric\/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study","volume":"6","author":"Long","year":"2025","journal-title":"Med"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.2147\/DDDT.S548735","article-title":"Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Qin, W., Du, Y., Zhao, X., Zhao, Y., Zhang, Y., Zhang, S., Yang, Z., Li, X., Niu, J., and Zhao, D. (2025). Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: A retrospective real-world study. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1654425"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhuang, Q., and Liu, Y. (2026). Efficacy and safety of Cadonilimab in the treatment of recurrent\/metastatic and advanced cervical cancer: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1729380"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"100789","DOI":"10.1016\/j.esmoop.2023.100789","article-title":"How we treat esophageal squamous cell carcinoma","volume":"8","author":"Puhr","year":"2023","journal-title":"ESMO Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11739-020-02295-2","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: A patient-centred approach","volume":"15","author":"Lambotte","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e71210","DOI":"10.1002\/cam4.71210","article-title":"The Safety of Cadonilimab: A Systematic Review and Single-Arm Meta-Analysis","volume":"14","author":"Zhang","year":"2025","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/1759-7714.13338","article-title":"Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system","volume":"11","author":"Li","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11725","DOI":"10.2147\/OTT.S279858","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma","volume":"13","author":"Cui","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1348\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:08:59Z","timestamp":1787742539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091348"],"URL":"https:\/\/doi.org\/10.3390\/ph19091348","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}